JP2017519008A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017519008A5 JP2017519008A5 JP2016572697A JP2016572697A JP2017519008A5 JP 2017519008 A5 JP2017519008 A5 JP 2017519008A5 JP 2016572697 A JP2016572697 A JP 2016572697A JP 2016572697 A JP2016572697 A JP 2016572697A JP 2017519008 A5 JP2017519008 A5 JP 2017519008A5
- Authority
- JP
- Japan
- Prior art keywords
- serelaxin
- pharmaceutical formulation
- patient
- biological sample
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 19
- DTLOVISJEFBXLX-REAFJZEQSA-N relexan 2 Chemical compound C([C@H]1C(=O)N[C@H](C(=O)NCC(=O)N[C@H]2CSSC[C@@H](C(=O)N[C@H](C(N1)=O)CSSC[C@@H](C(NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H]([C@@H](C)O)NC2=O)C(O)=O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CO)C(O)=O)[C@@H](C)CC)[C@@H](C)CC)C(C)C)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(O)=O)C(C)C)[C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DTLOVISJEFBXLX-REAFJZEQSA-N 0.000 claims 18
- 229960002792 serelaxin Drugs 0.000 claims 18
- 239000012472 biological sample Substances 0.000 claims 11
- 102000000597 Growth Differentiation Factor 15 Human genes 0.000 claims 7
- 108010041834 Growth Differentiation Factor 15 Proteins 0.000 claims 7
- 238000001802 infusion Methods 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 210000002966 serum Anatomy 0.000 claims 4
- 206010037368 Pulmonary congestion Diseases 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 230000004083 survival effect Effects 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 1
- 238000004393 prognosis Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462011744P | 2014-06-13 | 2014-06-13 | |
| US62/011,744 | 2014-06-13 | ||
| PCT/IB2015/054399 WO2015189790A1 (en) | 2014-06-13 | 2015-06-10 | Use of serelaxin to reduce gdf-15 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017519008A JP2017519008A (ja) | 2017-07-13 |
| JP2017519008A5 true JP2017519008A5 (cg-RX-API-DMAC7.html) | 2018-07-19 |
| JP6820748B2 JP6820748B2 (ja) | 2021-01-27 |
Family
ID=53476944
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016572697A Expired - Fee Related JP6820748B2 (ja) | 2014-06-13 | 2015-06-10 | Gdf−15を減少させるためのセレラキシンの使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20170100460A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3154559B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6820748B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20170018829A (cg-RX-API-DMAC7.html) |
| CN (1) | CN106413740A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2015273097A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112016028833A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2952061A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2016016414A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2016147122A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015189790A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1225742A1 (zh) | 2013-08-22 | 2017-09-15 | Acceleron Pharma, Inc. | TGF-β受体II型变体及其用途 |
| EP4005585B1 (en) | 2013-11-21 | 2024-03-27 | The Brigham & Women's Hospital, Inc. | Compositions and methods for treating right ventricular hypertrophy |
| EP3174550B1 (en) * | 2014-08-01 | 2020-01-29 | The Brigham and Women's Hospital, Inc. | Methods and compositions relating to treatment of pulmonary arterial hypertension |
| EP3331550B1 (en) | 2015-08-04 | 2022-11-02 | Acceleron Pharma Inc. | Composition for treating myeloproliferative disorders |
| FI3628049T3 (fi) | 2017-05-04 | 2023-07-26 | Acceleron Pharma Inc | Tgf-beeta-reseptorin tyypin ii fuusioproteiineja ja niiden käyttöjä |
| CN114025675A (zh) * | 2019-06-20 | 2022-02-08 | 索尼集团公司 | 信息处理装置、信息处理方法和程序 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2009000914A (es) * | 2006-08-04 | 2009-06-18 | Hannover Med Hochschule | Medios y metodos para evaluar el riesgo de intervenciones cardiacas basadas en el factor 15 de diferenciacion del crecimiento. |
| ES2379104T3 (es) * | 2007-05-24 | 2012-04-20 | F. Hoffmann-La Roche Ag | Métodos para evaluar el fallo cardíaco en pacientes con fibrilación auricular utilizando péptidos GDF-15 |
| EA201500552A1 (ru) * | 2008-05-16 | 2016-07-29 | Кортера, Инк. | Лечение релаксином одышки, ассоциированной с острой сердечной недостаточностью |
| AU2012280474A1 (en) * | 2011-07-01 | 2014-01-16 | Bayer Intellectual Property Gmbh | Relaxin fusion polypeptides and uses thereof |
-
2015
- 2015-06-10 CA CA2952061A patent/CA2952061A1/en not_active Abandoned
- 2015-06-10 KR KR1020167034407A patent/KR20170018829A/ko not_active Withdrawn
- 2015-06-10 EP EP15730858.6A patent/EP3154559B1/en not_active Not-in-force
- 2015-06-10 AU AU2015273097A patent/AU2015273097A1/en not_active Abandoned
- 2015-06-10 RU RU2016147122A patent/RU2016147122A/ru not_active Application Discontinuation
- 2015-06-10 WO PCT/IB2015/054399 patent/WO2015189790A1/en not_active Ceased
- 2015-06-10 MX MX2016016414A patent/MX2016016414A/es unknown
- 2015-06-10 US US15/316,952 patent/US20170100460A1/en not_active Abandoned
- 2015-06-10 BR BR112016028833A patent/BR112016028833A2/pt not_active Application Discontinuation
- 2015-06-10 JP JP2016572697A patent/JP6820748B2/ja not_active Expired - Fee Related
- 2015-06-10 CN CN201580032028.6A patent/CN106413740A/zh not_active Withdrawn
-
2018
- 2018-03-29 AU AU2018202289A patent/AU2018202289A1/en not_active Abandoned
- 2018-09-21 US US16/137,770 patent/US20190022189A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017519008A5 (cg-RX-API-DMAC7.html) | ||
| Myles et al. | Importance of intraoperative oliguria during major abdominal surgery: findings of the restrictive versus liberal fluid therapy in major abdominal surgery trial | |
| Guo et al. | Platelet-derived Wnt antagonist Dickkopf-1 is implicated in ICAM-1/VCAM-1–mediated neutrophilic acute lung inflammation | |
| Ter Maaten et al. | Diuretic response in acute heart failure—an analysis from ASCEND-HF | |
| Yanishi et al. | Factors associated with the development of sarcopenia in kidney transplant recipients | |
| Peck-Radosavljevic et al. | Austrian consensus on the definition and treatment of portal hypertension and its complications (Billroth II) | |
| Behr | The diagnosis and treatment of idiopathic pulmonary fibrosis | |
| JP2015501297A5 (ja) | 医薬組成物、方法、診断キット | |
| RU2016147122A (ru) | Применение серелаксина для снижения gdf-15 | |
| Rodríguez et al. | Recommendations of the Infectious Diseases Work Group (GTEI) of the Spanish Society of Intensive and Critical Care Medicine and Coronary Units (SEMICYUC) and the Infections in Critically Ill Patients Study Group (GEIPC) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) for the diagnosis and treatment of influenza A/H1N1 in seriously ill adults admitted to the Intensive Care Unit | |
| Karavanaki et al. | Plasma high sensitivity C-reactive protein and its relationship with cytokine levels in children with newly diagnosed type 1 diabetes and ketoacidosis | |
| JP2016520573A5 (cg-RX-API-DMAC7.html) | ||
| Zhang et al. | The alleviative effects of metformin for lipopolysaccharide-induced acute lung injury rat model and its underlying mechanism | |
| Sarma et al. | Safety, complications and outcome of large volume paracentesis with or without albumin therapy in children with severe ascites due to liver disease | |
| Lazzeri et al. | Mechanical ventilation in the early phase of ST elevation myocardial infarction treated with mechanical revascularization | |
| Nazim et al. | Metabolic control and its variability are major risk factors for microalbuminuria in children with type 1 diabetes | |
| Zhang et al. | Value of three-dimensional speckle tracking echocardiography to assess left ventricular function in hyperuricemia patients | |
| Gores et al. | Plasma angiopoietin 2 concentrations are related to impaired lung function and organ failure in a clinical cohort receiving high-dose interleukin 2 therapy | |
| Sharma et al. | Alveolar macrophage activation in obese patients with obstructive sleep apnea | |
| Mederacke et al. | Renal function during treatment with adefovir plus peginterferon alfa‐2a vs either drug alone in hepatitis B/D co‐infection | |
| Roberts et al. | A novel way to investigate the effects of plasma exchange on antibiotic levels: Use of microdialysis | |
| Boussir et al. | Eosinophilic myocarditis and hypereosinophilic syndrome | |
| Rouini et al. | Oral substitution of melatonin in critical care: a pharmacokinetic study in patients with intracranial hemorrhage | |
| Elder et al. | Prevention and amelioration of rodent endotoxin-induced lung injury with administration of a novel therapeutic tripeptide feG | |
| Shinohara et al. | Telmisartan effectively improves insulin sensitivity in hypertensive patients with insulin resistance |